Ceftaroline fosamil: a new broad-spectrum cephalosporin
Open Access
- 1 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (Supplement), iii11-iii18
- https://doi.org/10.1093/jac/dkr095
Abstract
Ceftaroline fosamil, the prodrug of the active metabolite, ceftaroline, is a new, broad-spectrum cephalosporin recently approved in the USA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP). Ceftaroline has potent in vitro activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae, as well as common Gram-negative organisms. The high affinity of ceftaroline for penicillin-binding proteins is responsible for the potent activity observed against clinically relevant pathogens. With respect to the treatment of CABP, the activity of ceftaroline against pathogens such as S. pneumoniae, S. aureus, Haemophilus influenzae and Moraxella catarrhalis demonstrates coverage across a broad range of pathogens typically encountered in clinical practice. Ceftaroline is also very active against common pathogens seen in ABSSSIs such as S. aureus (methicillin-susceptible S. aureus and methicillin-resistant S. aureus) and Streptococcus pyogenes. Ceftaroline exhibits a dose-proportional pharmacokinetic profile, similar to other renally excreted cephalosporins, and has a well-tolerated safety profile consistent with the cephalosporin class. Ceftaroline fosamil is compatible via Y-site administration with many other commonly administered parenteral drugs.Keywords
This publication has 37 references indexed in Scilit:
- In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus IsolatesAntimicrobial Agents and Chemotherapy, 2010
- Effect of Ceftaroline on Normal Human Intestinal MicrofloraAntimicrobial Agents and Chemotherapy, 2010
- Affinity of Ceftaroline and Other β-Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2010
- Postantibiotic Effect of Ceftaroline against Gram-Positive OrganismsAntimicrobial Agents and Chemotherapy, 2009
- Molecular Basis and Phenotype of Methicillin Resistance in Staphylococcus aureus and Insights into New β-Lactams That Meet the ChallengeAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC TestingAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Evaluation of the Antimicrobial Activity of Ceftaroline against Cephalosporin-Resistant Isolates of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates Exhibiting Resistance to Penicillin, Amoxicillin, and CefotaximeAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Co-opting the Cell Wall in Fighting Methicillin-Resistant Staphylococcus aureus: Potent Inhibition of PBP 2a by Two Anti-MRSA β-Lactam AntibioticsJournal of the American Chemical Society, 2008